Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB Pharma
This study is planned to provide information on how the body processes epratuzumab and how epratuzumab affects the body when epratuzumab is given once weekly for 4 weeks in a row at one of 2 different dose levels. Additional information will be obtained related to the natural variability of disease activity in SLE patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has SLE by American College of Rheumatology revised criteria (meets \>/= 4 criteria)
Has had SLE for at least 6 months prior to study entry
Has at least one elevated autoantibody level at study entry
Has moderately active SLE disease at study entry in any body/organ system (Full criteria not present here due to length of considerations. The protocols should be consulted regarding the complete list of entry criteria.)
You may not be if
Active Severe Lupus as defined by BILAG Index Level A in any body system or organ
